| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3519ea242d97a904badff9271f63de45
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a8e20137e10efebd66f7b326dc42151 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-27 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18 |
| filingDate |
2017-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6123e9451ff64f74e53066892c9c47b6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2e5e86397bc8bb0eb8f3813aeb5e3c53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_81a86c21e8b8f56228d18fb5ffe63e0f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d4b1a58beb615b535dc1d6761b569583
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7f53066e2c96d4020d6fb15ec1b3665e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5336d96f2c6f79d992cc3e77821c3f97
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df6ad17cb999849a87b4ea0f409bf6fa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e7cf2d7304838ae70e271e1573f1f394
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1a55e2d7c355895acd083b5ef4d06e03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_12a90f0449c6d100e6c134378d7def7b |
| publicationDate |
2017-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2017142331-A1 |
| titleOfInvention |
Pharmaceutical composition comprising recombinant hgh for the treatment of growth hormone deficiency |
| abstract |
Provided is a method for administering a recombinant human growth hormone GX-H9 for treating growth hormone deficiency. Particularly, the present disclosure relates to a pharmaceutical composition for treating growth hormone deficiency, containing a recombinant hGH GX-H9 and a pharmaceutically acceptable carrier, in which the recombinant GX-H9 is administered once a week with a dosage of 0.1 to 0.3 mg per weight kg of a patient or twice-monthly with a dosage of 0.1 to 0.4 mg per weight kg of the patient. Further, the present disclosure relates to a method for treating growth hormone deficiency including administering an recombant hGH GX-H9 to a patient with growth hormone deficiency once a week with a dosage of 0.1 to 0.3 mg per weight kg of the patient or twice-monthly with a dosage of 0.1 to 0.4 mg per weight kg of the patient. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3506923-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TW-I718334-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018044060-A1 |
| priorityDate |
2016-02-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |